The exclusive mycobacterial cell wall lipids such as trehalose monomycolate and dimycolate (TMM, TDM), phthiocerol dimycocerosate (PDIM), sulpholipid-1 (SL-1), diacyl trehalose (DAT), and pentacyl trehalose (PAT), among others, are known to play an important role in pathogenesis; thus, proteins responsible for their transport are potential virulence factors. MmpL and MmpS proteins mediate transport of important cell wall lipids across the mycobacterial membrane. In Mtb, MmpL3, MmpL7 and MmpL8 transport TMM, PDIM and SL-1 respectively. The translocation of DAT and biosynthesis of PAT is likely due to MmpL10. MmpL and MmpS proteins are involved in other processes such as drug efflux (MmpL5 and MmpL7), siderophore export (MmpL4/MmpS4 and MmpL5/MmpS5), and heme uptake (MmpL3 and MmpL11). Altogether, these proteins can be regarded as new potential targets for antituberculosis drug development. We will review recent advances in developing inhibitors of MmpL proteins, in the challenging context of targeting membrane proteins and the future prospects for potential antituberculosis drug candidates. 
Tuberculosis along history
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, has been present in the human population since antiquity. Initially, it was thought that during the domestication of animals in the Neolithic period, Mycobacterium bovis strains from infected cattle evolved and acquired the capability of infecting humans, hence originating human tuberculosis [1] . However, it is now widely accepted that the ancients Mtb strains were originated from environmental mycobacteria 70 000 years ago in Africa [2, 3] . The introduction of agriculture, civilization and the increase in human population density led to the selection of virulent and transmissible Mtb strains. These modern Mtb strains spread throughout the world causing the tuberculosis epidemics that ravaged mankind for centuries [4] .
Nowadays, 9 million people fell ill with tuberculosis and 1.5 million died in 2013 (including 360 000 deaths among HIV-positive people) according to the most recent report of the World Health Organization (WHO) [5] . At present, tuberculosis is the second leading cause of death from an infectious agent worldwide, after the Human Immunodeficiency Virus (HIV), in spite of the fact that we have powerful tools in order to face tuberculosis: vaccination, diagnostics and treatments.
Tuberculosis treatment and drug resistance
Page 5 of 39 A c c e p t e d M a n u s c r i p t 5 Drug treatment is the only effective therapy for tuberculosis. Drugs are classified into three groups (Table 1) based on evidence of efficacy, potency and experience of use [6] .
 First-line antituberculosis drugs are the most effective and widely used drugs for the treatment of drug-susceptible tuberculosis.
 Second-line antituberculosis drugs are reserved for treating bacilli resistant to first-line therapy. A drug may be classed as second-line instead of first-line for being less effective than the first-line drugs (e.g. para-aminosalicylic acid), having toxic side-effects (e.g. cycloserine) or being effective, but unavailable in many developing countries (e.g. fluoroquinolones).
 Third-line antituberculosis drugs are characterized for being less effective (e.g. clarithromycin) or because their efficacy has not been fully proven (e.g. clofazimine).
With appropriate antibiotic treatment, around 90% of HIV-negative patients with drugsusceptible tuberculosis can be cured in 6 months using a combination of rifampicin (Rif), isoniazid (Inh), pyrazinamide (Pza) and ethambutol (Emb) for 2 months, followed by a four-month continuation phase of Rif and Inh [5] . The main reason for prescribing this combination of medicines in the treatment of tuberculosis is because the likelihood of the emergence of multiple drug resistance bacteria is virtually impossible [7] , apart from the fact that the distinct antituberculosis drugs have different modes of action: Inh are bactericidal against replicating bacteria; Emb is Page 6 of 39 A c c e p t e d M a n u s c r i p t 6 bacteriostatic at low doses, but is used in tuberculosis treatment at higher, bactericidal doses; Rif is bactericidal and has a sterilizing effect; and Pza is only weakly bactericidal, but is very effective against bacteria located in acidic environments, inside macrophages, or in areas of acute inflammation, where they enter into a non-replicative condition. Thus, the combination of all these drugs targets all subpopulations of Mtb, i.e. those actively replicating and those in a non-replicative state.
Monotherapy, irregular drug supply, poor drug quality, inappropriate prescription, poor adherence to treatment and unsuitable supervision and support on the part of health personnel, can contribute to appearance and selection of drug-resistant Mtb strains that can disseminate and cause drug resistant tuberculosis. Depending on the drug resistance pattern, three major categories have been defined:
 Multidrug-resistant (MDR) strains are those resistant to Inh and Rif. In 2013, the highest levels of MDR tuberculosis were found in Eastern Europe and central Asia, where in some countries more than 20% of new tuberculosis cases and more than 50% of those previously treated for tuberculosis have MDR tuberculosis [5] . active antiretroviral therapy was 98%, after a median survival period from diagnosis of only 16 days [8] .
 Totally drug-resistant (TDR) refers to strains that are resistant to all available tuberculosis drugs, although the number and level of resistance to each drug
has not yet been precisely defined. To date, only a limited number of TDR tuberculosis cases have been confirmed in Iran, India, South Africa and Italy [9] .
All these are cases of acquired resistance [7] . The mechanisms by which bacteria in general acquired drug resistance are: barrier mechanisms (decreased permeability/increased efflux), degrading/inactivating enzymes, modification of pathways involved in drug activation/metabolism, and drug target modification (mutations) or target amplification [10] . Mtb in particular is able to acquire drug resistance by spontaneous mutations in chromosomal genes then leading to target modification, target amplification, reduced ability for activating drugs, or increased capacity for inactivating drugs ( Table 2) ; no horizontal transfer of resistance genes had been reported [11] .
Mycobacterial cell envelope: biochemically complex, pharmacologically interesting
The mycobacterial envelope is unique, both in molecular composition and in the architectural arrangement of its constituents ( Fig. 1 ; adapted from [12, 13] ). Its complex structure is composed of a typical phospholipid bilayer plasma membrane, an outer membrane called mycomembrane, and an outermost layer known as the capsule. The plasma membrane is composed mainly of anionic phospholipids in a bilayer arrangement with proteins. The mycomembrane consists of an asymmetric lipid bilayer made of long chain (C60-C90) mycolic fatty acids in the inner leaflet, and free intercalating glycolipids and waxy components on the outer leaflet. Cryo-electron microscopy images support a folded or compact configuration of these mycolic chains, which reminiscent of Gram-negative bacterial cell walls [14] [15] [16] , and also confirm that the measured thickness of the outer membrane is consistent with the size of mycobacterial porins, such as MspA from M. smegmatis, which may therefore form channels in this bilayer [14] . The outer and inner membrane form a periplasmic space, with the presence of a thin layer of peptidoglycan covalently linked to arabinogalactan and lipoarabinomannan, which in turn are bound to mycolic acids.
Peptidoglycan, arabinogalactan and mycolic acids form the cell wall skeleton. The capsule is mainly composed of polysaccharides, proteins and small amounts of lipids, and it is considered to have a different molecular composition in pathogenic and non-pathogenic species [17] . The outermost layer is visible in conventional electron microscopy preparations only when cultures have been grown in free detergent medium. It is thought that mycobacterial growth under laboratory routine culturing conditions (with a detergent as Tween-80) promotes removing of this layer [13] .
The mycobacterial envelope is involved in important roles, such as defining the [19, 20] . Similarly, PIMs and mannose-capped lipoarabinomannan (Man-LAM) both interfere with phagosome maturation [21] .
In summary, proper localization of lipids in the mycobacterial cell wall, mostly in the outermost layer, is needed for their role in pathogenicity, thus making transport of lipids an essential process in mycobacterial cells. Proteins transporting lipids are therefore important virulence factors and attractive drug targets.
Proteins for lipid transport in M. tuberculosis
Efflux pumps are membrane proteins that transport actively a wide variety of compounds across bacterial envelope. They have been classified into five superfamilies: ATP-binding cassette (ABC), major facilitator super-family (MFS), resistance nodulation division (RND), small multidrug resistance (SMR) and multidrug and toxic-compound extrusion (MATE). While MFS, SMR, RND and MATE members are secondary transporters, typically energized by the proton motive force (H + or Na + ), members of the ABC superfamily use ATP as the energy source and are considered as primary transporters [22] . Whereas efflux pumps are mostly known because of the transport of drugs from the cytoplasm, other efflux pump substrates has been confirmed [23, 24] , but the role of mce1, mce2 and mce3 operons is not clearly established, especially in the case of the mce3 operon. As regards to mce1 operon, it has been suggested that these proteins may serve as a mycolic acid reimporter [25] , and mce2 operon might be related in sulpholipid transport [26] . Due to their most probable implication in lipid metabolism, the Mce proteins may modulate pathogenicity through changes in Mtb lipid pathways.
A special case for lipid transport: the MmpL and MmpS families of proteins
The transport of lipids in Mtb is predominantly via a family of proteins termed MmpL proteins (Mycobacterial Membrane Protein Large) belonging to the RND family of membrane proteins. The Mtb genome possesses 15 different genes encoding for RND proteins [27] , 13 of which belong to MmpL (Table 3 ) protein family. Mutants with disruptions in mmpL2, mmpL4, mmpL5, mmpL7, mmpL8, mmpL10, and mmpL11 showed significant attenuation for growth in mice lungs [20, [28] [29] [30] . Notably, the first Mtb genome also revealed that many clusters harbouring polyketide synthase genes with a known or putative role in lipid biosynthesis also contained an mmpL gene Page 12 of 39 A c c e p t e d M a n u s c r i p t 12 suggesting that the function of the mmpL gene was associated with the cognate lipid species produced by the enzymes encoded by the cluster. The first role for MmpLs in lipid transport was demonstrated by Cox et al [31] who isolated an mmpL7 mutant from a signature-tag mutagenesis screen. The mutant was found to be defective in PDIM transport and found to accumulate the complex lipid intracellularly [31] . mmpL7 is present in the same cluster that encodes enzymes responsible for the biosynthesis of the pthiocerol (ppsA-E) and mycocerosic acid (mas) moieties of PDIM.
Subsequently, another MmpL protein, MmpL8 was shown to be involved in the transport of SLs [29, 32] . Interestingly, while no sulpholipid-1 (SL-1) was detected in the cell envelope of Mtb, the mmpL8 mutant accumulated an intermediate of SL-1, termed SL-1278, indicating that some, if not all MmpLs were involved in transporting intermediates, which were consequently processed further outside the cell [29, 32] .
More recently, the functions of other mmpL genes have been deciphered.
MmpL10 was shown to be involved in the translocation of acylated trehaloses; loss of mmpL10 function led to intracellular accumulation of DATs [33] . Additionally, PATs were missing from the cell surface, indicating that the translocation of DATs by MmpL10 was likely required for the subsequent acylation of DAT substrates to yield extracellular PATs. MmpL proteins are also involved in the transport of mycolic acid derived lipids. mmpL3, the only essential mmpL gene in Mtb was shown to be involved in the transport of TMM [34, 35] using a conditional mutant of the mmpL3 homologue of Mycobacterium smegmatis. Furthermore, mmpL11, located in the same cluster as mmpL3 was shown to be involved in the export of monomeromycolyl diacylglycerol (MMDAG) [36] .
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A c c e p t e d M a n u s c r i p t 13 There is also a growing line of evidence that suggests the MmpLs are not just transporters, but may be involved in the formation of membrane-associated scaffolds that facilitate the coupling of lipid biosynthesis with transport. Four mmpL containing clusters in Mtb also contain a gene encoding an MmpS protein (Mycobacterial Membrane Protein Small). In M. smegmatis, MmpS4 was shown to be required for biosynthesis and export of a surface exposed glycopeptidolipid [37] . A domain of MmpL7 was shown to interact PpsE, an enzyme involved in PDIM biosynthesis [38] .
MmpL3 was also shown to co-localise with meromycolate producing FAS-II complex components at the septa and poles of the mycobacterial cell [39] .
Other roles for MmpL and MmpS proteins in M. tuberculosis
Besides lipid transport, MmpL and MmpS proteins are involved in other bacterial processes, including drug resistance and siderophore export [40] (MmpL4/MmpS4 and MmpL5/MmpS5), and heme uptake [41, 42] (MmpL3 and MmpL11); the acquisition of iron is an essential attribute of pathogenic bacteria so as to establish a successful infection.
a) Drug resistance
Early studies suggested that MmpL proteins did not play a significant role in intrinsic resistance to drugs in Mtb [30] ; although this seems to be the general case econazole and other substrates from cells [43] . In recent years, these proteins were linked to cross-resistance between clofazimine (a traditional drug to treat leprosy, which is also considered as a third-line drug for use against drug resistant tuberculosis) and bedaquiline (a recently approved drug for treatment of MDR tuberculosis) [44, 45] . In all cases, drug resistance was mediated by increased transcription of these two genes, mediated by mutations in a regulatory protein encoded by Rv0678 gene; the latter could probably regulate as well expression of mmpL4-mmpS4 and mmpL2 -mmpS2 [46] .
Evidences about a role for MmpL7 transporter in isoniazid resistance are still controversial: isoniazid readily increases transcription of mmpL7 gene in Mtb [47] , although overexpression of mmpL7 gene only resulted in resistance to isoniazid in the heterologous host M. smegmatis [48] .
The link between MmpL3 and drug resistance seems to be indirect and has not been fully characterised yet. MmpL3 interacts with Wag31 protein as a part of a large network of interactions between proteins involved in fatty acid metabolism; as a consequence of Wag31 knock-down, resistance to lipophilic drugs was altered [49] . proteins that will transport iron-containing heme groups through the mycobacterial membrane into the cytoplasm, where MhuD protein will degrade heme group releasing its iron content [41] . Second strategy consists on producing and exporting siderophores (mycobactins and carboxymycobactins) that will bind non-heme iron outside the bacterial cell. MmpS4 and MmpS5 proteins resulted essential for producing and releasing siderophores, hence indicating a role for MmpL4-MmpS4 and MmpL5-MmpS5 protein complexes in exporting siderophores in Mtb [40] . Ironcontaining siderophores are subsequently uptaken by a pathway independent of MmpL4-MmpS4 and MmpL5-MmpS5, which complete the siderophore recycling system; in those mutants lacking MmpS4 and MmpS5 proteins, siderophores then accumulate in the cytoplasm resulting in lethality for the bacteria [50] .
b) Iron acquisition

Inhibitors of MmpL proteins: new drugs for the future?
MmpL proteins have been investigated for their contribution to virulence, drug resistance, and other processes in Mtb for more than a decade, but it was just in the last three years when MmpL3 (that had been predicted to be the only essential protein of this family [30] ) emerged as a drug target. From 2012, several families of structurally different chemical entities have been shown to inhibit MmpL3 (Table 4) opening a new field in the inhibition of mycolic acids transport [34, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] . Notably, compound SQ109, which was identified a decade ago in a combinatorial chemistrybased search for ethambutol analogues, currently on phase III of clinical trials, was revealed as an inhibitor of MmpL3 [54] .
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A c c e p t e d M a n u s c r i p t 16 Discovering a brand new drug target in Mtb along with 7 new families of potential inhibitory compounds in such a short period of time seemed like a success in antituberculosis drug discovery never before seen. Further investigation into their mechanism of action demonstrated that most of these compounds are also targeting several enzymes in the menaquinone biosynthesis pathway and electron transport chain; as a consequence, respiration and ATP synthesis were inhibited and the transmembrane electrochemical proton gradient (the energy source in many transport processes) were abolished [63, 64] . Then, since multiple protein targets can be affected simultaneously, the probability of selection of resistant mutants remains very low for most of these compounds. Also, given that the electrochemical gradient, a general process in many cells, is targeted, compounds in this group such as SQ109, BM212 [55, 58] and the THPPs [60] have shown to be active against other bacterial and fungal pathogens lacking mycolic acids and MmpL3-related targets. In any case, the activity of these compounds against drug resistant and MDR isolates of Mtb and their synergy with current antituberculosis therapy (notably in the case of SQ109) makes conceivable the possibility to shorten current antituberculosis treatment, one of the key points that will be essential in the near future to control this terrible disease. to that in Gram-negative bacteria, where efflux-mediated drug resistance is prominent in many pathogens [65] .
Future directions: the impact of MmpL proteins & lipid transport in antituberculosis drug discovery
Being enthusiastic about the role of transport proteins in drug resistance, we suggested that efflux pumps could have a role in transporting new drugs in development, and hence they should be taken into account in antituberculosis drug discovery programmes [66] . Recently, several publications have confirmed this hypothesis, and transport proteins were genetically related with resistance to peptidoglycan synthesis inhibitors [67] and several other families of new compounds with antituberculosis activity [68, 69] . Notably, among a series of spectinomycin derivatives, the most active molecules were those that escaped transport by the Rv1258c efflux pump [70] . Similarly, this has been the case for the MmpL5 protein since it has been demonstrated to transport bedaquiline [44, 45] . Altogether, it becomes clear that efflux transporters must be taken into consideration in any tuberculosis drug discovery programs in order to estimate the likelihood of the new molecules for being transported out of bacterial cells.
One of the most successful approaches in antimicrobial therapy has been the combination of beta-lactam antibiotics with inhibitors of beta-lactamases, and this has inspired a similar strategy for drug transport proteins [66, 71] . For years, this approached seemed unrealistic, given the toxicity of most efflux inhibitors, which remained useful only under laboratory conditions to demonstrate efflux mechanism.
However, discovery of several MmpL3 inhibitors on recent years has brought the attention back to this field. Being a transport protein of the RND superfamily, MmpL3
Page 18 of 39 A c c e p t e d M a n u s c r i p t 18 is however rather distinct from conventional efflux pumps of the same family such as AcrAB-TolC from E. coli, in terms of substrate specificity and transport activity:
whereas AcrAB-TolC has a clear role in detoxification by transporting out antibiotics and other noxious products, MmpL3 has a major role as both a trehalose monomycolate (TMM) transporter (hence contributing to the assembly of mycobacterial cell envelope) and a heme importer [34, 35, 42] . It is tempting to believe that inhibiting a protein involved in two such different and important pathways is like having found the Achilles' heel of Mtb. In addition, since several of these MmpL3 inhibitors act by dissipating the proton gradient, which is the energy source used by MmpL3 itself and many other transport proteins [63, 64] , it is expected that lipid transport in general (not only TMM transport) would be greatly affected, given the implication of other MmpL proteins in the transport of other essential lipids (PDIM in the case of MmpL7, sulpholipid-1 in the case of MmpL8, acylated trehaloses in the case of MmpL10, and monomeromycolyl diacylglycerol in the case of MmpL11).
In summary, MmpL proteins have emerged also as attractive drug targets in Mtb, given their pivotal role in lipid transport (and other essential processes) in this pathogen. Including specifically MmpL proteins in drug discovery programmes could be challenging, given the intrinsic difficulty to work with membrane proteins, but this should be overcome by the expectations of finding a new effective drug candidate against tuberculosis.
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